


Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 1 of 1

Complete if Known

<b>Application Number</b>	10/081,050
<b>Filing Date</b>	February 20, 2002
<b>First Named Inventor</b>	Osborne, David
<b>Group Art Unit</b>	1615
<b>Examiner Name</b>	Channavajjala, Lakshmi

Attorney Docket No: 1195.346US1

**US PATENT DOCUMENTS**

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
X	US-4,829,058	05/09/1989	Seydel, Joachim K., et al.	06/15/1987
	US-4,912,112	03/27/1990	Seydel, Joachim , et al.	02/06/1987
	US-5,733,572	03/31/1998	Unger, Evan C., et al.	11/29/1994
	US-6,056,955	05/02/2000	Fischetti, V. , et al.	09/14/1999
	US-6,248,324	06/19/2001	Fischetti, Vincent , et al.	09/28/2000
✓	US-6,254,866	07/03/2001	Fischetti, Vincent , et al.	09/01/2000
✓	US-6,277,399	08/21/2001	Fischetti, Vincent , et al.	09/28/2000

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓		COLEMAN, MICHAEL D., et al., "Preliminary evaluation of the toxicity and efficacy of novel 2,4-diamino-5-benzylpyrimidine-sulphone derivatives using rat and human tissues in vitro", <u>Environmental Toxicology and Pharmacology</u> , 2(4), (December 20, 1996),389-395	
		COLEMAN, MICHAEL D., et al., "Studies on the inhibitory effects of analogues of dapsone on neutrophil function in vitro", <u>J. Pharm. Pharmacol.</u> 49(1), (January 1997),53-57	
✓		COLEMAN, MICHAEL D., et al., "Studies on the toxicity of analogues of dapsone in-vitro using rat, human and heterologously expressed metabolizing systems", <u>J. Pharm. Pharmacol.</u> , 48(9), (September 1996),945-950	

EXAMINER

L. Channavajjala

DATE CONSIDERED

6/15/05